Trials / Completed
CompletedNCT04689516
Thoracic Fluid Content During Hypervolemic Hemodilution
The Use of Thoracic Fluid Content as a Guide for 6% HES Infusion During Hypervolemic Hemodilution in Patients With Placenta Accreta. A Randomized Controlled Trial.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Cairo University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Thoracic fluid content (TFC) is one of the many variables measured by the ICON electrical cardiometry (EC) device (Osypka Medical). The ICON device is often called "thoracic electrical bio-impedance" that based on measuring the changes in total resistance of the thorax to electric current and is considered a numerical measure of total (intravascular and extravascular) thoracic fluid. Although TFC is a measure of both extra and intra-vascular thoracic fluid, it provides an estimate of the increase in intrathoracic fluids such as to facilitate the risk of pulmonary edema. Although many studies were done on the ability of TFC to detect pulmonary edema in preeclampsia, ARDS, heart failure, weaning from mechanical ventilation and during fluid management in prolonged surgery , yet, there is no study before was done on the use of TFC as a guide for fluid therapy during hypervolemic hemodilution in major obstetric surgery in patients with placenta accreta as one of the most common etiologies of life-threatening obstetric hemorrhage and the most common cause of peripartum hysterectomy Aim of the work: To use TFC as a guide for 6% HES infusion of hypervolemic hemodilution in patients with placenta accreta to avoid fluid overload. Objectives: * To calculate LUS score at the end of infusion. * To evaluate TFC in k ohm-1. * To assess oxygen saturation, PO2 and P/F ratio in ABG. * To calculate the total infused volume in milliliters.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Thoracic fluid content estimation | The patient will be monitored for thoracic fluid content and LUS score. The infusion will stop if TFC reaches 40 k ohm-1 or after completion of the infused volume. LUS evaluation will be done before the start and after the end of the infusion. |
Timeline
- Start date
- 2020-12-24
- Primary completion
- 2021-12-30
- Completion
- 2022-01-02
- First posted
- 2020-12-30
- Last updated
- 2022-03-14
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT04689516. Inclusion in this directory is not an endorsement.